IVA

3.1408.99%
AO

Andrew Obenshain

Chief Executive Officer

Mr. Andrew Obenshain serves as Chief Executive Director at Inventiva S.A. since October 01, 2025 and served as its Director. He has been the Director of bluebird bio, Inc. since November 2021 and served as President since November 2021 until June 2025 and served as Chief Executive Officer. He served as President of Severe Genetic Diseases since October 2020 until November 2021. He served as Chief of Wings at bluebird bio, Inc. since 2020. Mr. Obenshain served as Senior Vice President and Head of Europe at bluebird bio, Inc. since December 2, 2016 until 2020. Mr. Obenshain was employed at BA Venture Partners in the position of Associate. Prior to that, from September 2015 to September 2016, Mr. Obenshain was the general manager of France and Benelux at Shire Pharmaceuticals, Inc. and from 2007 to 2015, he held roles of increasing responsibility at Genzyme/Sanofi. He served as an Associate at Scale Venture Partners. Mr. Obenshain received his MBA from Northwestern University’s Kellogg School of Management and his BA in Genetics, Cell and Developmental Biology from Dartmouth College.

Positions